{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:44:29Z","timestamp":1791477869062,"version":"4.3.4"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Vitamin D modulates bisphosphonate (BP) efficacy, but its contribution to bone mineral density (BMD) after BP discontinuation is not known. To address this topic, we performed a retrospective analysis of postmenopausal women exposed to alendronate (ALN) to treat osteoporosis who regularly continued the supplementation of cholecalciferol or calcifediol at recommended doses. In the ninety-six recruited women (age 61.1 \u00b1 6.9 years), ALN was administered for 31.2 \u00b1 20.6 months and then discontinued for 33.3 \u00b1 18.9 months. The modification of 25(OH)D serum levels over time was associated with a change of alkaline phosphatase (r = \u22120.22, p = 0.018) and C-terminal collagen type 1 telopeptide (r = \u22120.3, p = 0.06). Women in the tertile of the highest increase in 25(OH)D level showed a 5.7% BMD gain at lumbar spine, that was twice as great in comparison with participants with a lower 25(OH)D variation. At a multiple regression analysis, BMD change was associated with time since menopause (\u00df = 2.28, SE 0.44, p &lt; 0.0001), FRAX score for major fracture (\u00df = \u22120.65, SE 0.29, p = 0.03), drug holiday duration (\u00df = \u22122.17, SE 0.27, p &lt; 0.0001) and change of 25(OH)D levels (\u00df = 0.15, SE 0.03, p = 0.0007). After ALN discontinuation, improving the vitamin D status boosts the ALN tail effect on BMD.<\/jats:p>","DOI":"10.3390\/nu13061878","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:45:29Z","timestamp":1622432729000},"page":"1878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-2299","authenticated-orcid":false,"given":"Antonino","family":"Catalano","sequence":"first","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"},{"name":"Department of Endocrinology and Diabetes and Bone-Metabolic Research Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-4921","authenticated-orcid":false,"given":"Federica","family":"Bellone","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Santoro","sequence":"additional","affiliation":[{"name":"Unit and School of Nephrology, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes and Bone-Metabolic Research Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-9606","authenticated-orcid":false,"given":"Agostino","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Unit and School of Internal Medicine, Department of Clinical and Experimental Medicine, University of Catania, Policlinico \u201cG. Rodolico\u201d, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Basile","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Sottile","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Atena","family":"Stoian","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-5057","authenticated-orcid":false,"given":"Francesco","family":"Corica","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziata","family":"Morabito","sequence":"additional","affiliation":[{"name":"Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico \u201cG. Martino\u201d, Via C. Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11657-020-0697-8","article-title":"Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: A meta-epidemiological study","volume":"15","author":"Kataoka","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled Trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of Risedronate on the Risk of Hip Fracture in Elderly Women","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten Years\u2019 Experience with Alendronate for Osteoporosis in Postmenopausal Women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of Continuing or Stopping Alendronate After 5 Years of Treatment","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis","volume":"75","author":"Sorensen","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1517\/14656566.2015.1087506","article-title":"The use of bisphosphonates in women: When to use and when to stop","volume":"16","author":"Gatti","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture Prevention With Vitamin D Supplementation","volume":"293","author":"Willett","year":"2005","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","article-title":"A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention","volume":"367","author":"Willett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/archinternmed.2008.600","article-title":"Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency","volume":"169","author":"Willett","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Atteritano, M., Mirarchi, L., Venanzi-Rullo, E., Santoro, D., Iaria, C., Catalano, A., Lasco, A., Arcoraci, V., Gullo, A.L., and Bitto, A. (2018). Vitamin D Status and the Relationship with Bone Fragility Fractures in HIV-Infected Patients: A Case Control Study. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010119"},{"key":"ref_20","first-page":"38","article-title":"Current nutritional recommendations and novel dietary strategies to manage sarcopenia","volume":"2","author":"Calvani","year":"2013","journal-title":"J. Frailty Aging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1447-0594.2010.00668.x","article-title":"Vitamin D hormone: A multitude of actions potentially influencing the physical function decline in older persons","volume":"11","author":"Cesari","year":"2010","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"P23","DOI":"10.1530\/EJE-18-0736","article-title":"Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: A position statement of the European Calcified Tissue Society","volume":"180","author":"Lips","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1359\/jbmr.060715","article-title":"Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study","volume":"21","author":"Adami","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-008-0650-y","article-title":"Vitamin D status and response to treatment in post-menopausal osteoporosis","volume":"20","author":"Adami","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-009-9295-x","article-title":"Minimum Required Vitamin D Level for Optimal Increase in Bone Mineral Density with Alendronate Treatment in Osteoporotic Women","volume":"85","author":"Ishijima","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40618-015-0299-2","article-title":"Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate","volume":"38","author":"Catalano","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: Meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/PPA.S95634","article-title":"Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis","volume":"10","author":"Calabria","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40618-020-01220-w","article-title":"Vitamin D screening","volume":"43","author":"Minisola","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D Deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1532-5415.2007.01161.x","article-title":"Secondary Hyperparathyroidism Due to Hypovitaminosis D Affects Bone Mineral Density Response to Alendronate in Elderly Women with Osteoporosis: A Randomized Controlled Trial","volume":"55","author":"Barone","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00223-012-9577-6","article-title":"Vitamin D Reduces Musculoskeletal Pain After Infusion of Zoledronic Acid for Postmenopausal Osteoporosis","volume":"90","author":"Catalano","year":"2012","journal-title":"Calcif. Tissue Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF03347375","article-title":"High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture","volume":"29","author":"Giusti","year":"2006","journal-title":"J. Endocrinol. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11739-011-0628-1","article-title":"Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression","volume":"8","author":"Atteritano","year":"2011","journal-title":"Intern. Emerg. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","first-page":"331","article-title":"Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?","volume":"64","author":"Bandeira","year":"2020","journal-title":"Arch. Endocrinol. Metab."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/6\/1878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:14Z","timestamp":1760162954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/6\/1878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["nu13061878"],"URL":"https:\/\/doi.org\/10.3390\/nu13061878","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}